Radiopharmaceuticals are emerging as a development platform rather than a single modality in oncology. This article explores what that means for cancer drug development and how integrated strategies can reduce risk and accelerate progress to the clinic.

Stop costly biologic failures. This masterclass reveals high-throughput strategies to optimize antibody leads upfront.

Researchers have developed a new class of stable boron compounds that could make it easier to improve existing medicines, allowing developers to fine-tune effectiveness without rebuilding drugs from scratch.

Scientists have discovered a hidden communication system inside bacteria that allows them to share genetic information and develop resistance to multiple antibiotics.

New research has revealed that tau-driven neurodegenerative diseases each have distinct chemical signatures, challenging current one-size-fits-all approaches to diagnosis and treatments.

Researchers have developed 3D human brain organoids that reveal how glioblastoma interacts with brain and immune cells, discovering hidden drivers of tumour invasion.

A single-dose gene-editing therapy has shown it can correct the genetic cause of autosomal dominant polycystic kidney disease in preclinical models, slowing cyst growth, improving organ health and potentially leading to future treatments that target the disease at its source.

Scientists have identified early blood biomarkers for Parkinson’s disease, revealing a narrow window in which the condition could be detected years before symptoms appear.

Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.

Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.

Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.